


FIG. 1



EVALUATION ITEM

- MEASUREMENT OF VIRAL TITER OF VAGINAL DOUCHE
[VIRUS SHEDDING SUPPRESSION EFFECT]
- VAGINAL LESION SYMPTOM SCORE
[DISEASE PREVENTION EFFECT]

FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51




FIG. 52




FIG. 53




FIG. 54




FIG. 55




FIG. 56




FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61





FIG. 62

inoculation (INTRACEREBRAL)
(1×10^4 PFU)



EVALUATION ITEM

- DETERMINE SURVIVAL OR DEATH AFTER INTRACEREBRAL ADMINISTRATION OF RECOMBINANT LIVE ATTENUATED VACCINE TO MOUSE [SAFETY]

FIG. 63




FIG. 64




FIG. 65




FIG. 66




FIG. 67




FIG. 68




FIG. 69




FIG. 70




FIG. 71




FIG. 72





FIG. 73



EVALUATION ITEM

- DETERMINE SURVIVAL OR DEATH AFTER ADMINISTRATION OF RECOMBINANT LIVE ATTENUATED VACCINE TO MOUSE NASAL MUCOSA [SAFETY]

FIG. 74




FIG. 75




FIG. 76




FIG. 77




FIG. 78





FIG. 79

Vaccine (NASAL OR
INTRAMUSCULARLY INJECTED)
(1×10^6 PFU: TWICE
OR 1×10^7 PFU: TWICE)



Challenge (VAGINAL)
MS (1×10^5 PFU)

↑ challenge 2weeks ↑ Vaccine 2weeks ↑ Vaccine 5weeks

EVALUATION ITEM

- CALCULATE RECURRENCE SUPPRESSION RATE FROM CUMULATIVE NUMBER OF TIMES OF RECURRENCE OF UNVACCINATED GROUP AND VACCINATED GROUP [RECURRENCE PREVENTION EFFECT]

FIG. 80




FIG. 81




FIG. 82




FIG. 83

